2023 Targeted Therapies of Lung Cancer Meeting

Promotion, Advertising & Exhibits

Fact: As of 2020, the #lungcancer survival rate increased 14.5% over the last five years nationally to 23.7%, yet remains significantly lower among communities of color at 20.0%, and Black Americans at 18.0%. #LCAM22 #LCSM

This guideline reflects a new staging system for people with #thymoma and #thymiccarcinoma which includes recommendations developed to improve management of #thymic epithelial tumors in patients.
https://bit.ly/3GDqHXp #LCSM

The #EUCancerPlan introduced new #lungcancer screening recommendations based on the latest technology, scientific developments & evidence in 3 key areas: access, quality, & diagnostics with a focus on increasing the number of earlier diagnoses. https://bit.ly/3ghtnip #LCAM22

Fact: #Lungcancer screening is an opportunity to save lives. Screening with annual low-dose CT scans can reduce the lung cancer death rate by up to 20% by detecting tumors at early stages, when the cancer is more likely to be curable. #LCAM22 #LCSM

Load More

The IASLC 2023 Targeted Therapies of Lung Cancer Meeting (TTLC 2023) offers a tremendous opportunity to market to one of the leading gatherings of researchers, clinicians, and professionals in the field of lung cancer and thoracic oncology.

Contact Us

For information regarding promotion & advertising, symposia and exhibit opportunities, please contact: 

International Association for the Study of Lung Cancer (IASLC)
[email protected]